Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries

Table 3 Composite predictive models for advanced hepatic fibrosis in chronic liver disease

Biomarker panel	Components	Formula	Validated in adult NAFLD	Ref.
APRI index	AST, platelet count	Ratio	√	Kruger et al[96]
BAAT score	Age, BMI, ALT, triglycerides	Weighted sum	√	Ratziu et al[97]
BARD score	BMI, AST, ALT, DM II	Weighted sum	√	Harrison et al[98]
Cirrhosis discrimination score	AST, ALT, platelet count, INR	Weighted sum	×	Udell et al[99]
FIB-4 index	Age, AST, ALT, platelet count	Algorithm	√	Shah et al[100]
Fibrosis probability index	Age, AST, previous alcohol use, HOMA-IR, cholesterol	Algorithm	×	Sud et al[101]
Forns index	Age, platelet count, GGT, cholesterol	Algorithm	√	Forns et al[102]
Gholam's score	ALT, HbA1C	Weighted score	√	Gholam et al[53]
Hui model	BMI, bilirubin, albumin, platelet count	Algorithm	×	Hui et al[103]
King score	Age, AST, platelet count, INR	Algorithm	×	Cross et al[104]
Lok index	AST, ALT, platelet count, INR	Algorithm	×	Lok et al[105]
NAFLD fibrosis score	Age, BMI, platelet count, albumin, AAR, IFG/DM II	Algorithm	√	Angulo et al[106]

NAFLD: Non-alcoholic fatty liver disease; APRI: Aspartate aminotransferase to platelet ratio index; AST: Aspartate aminotransferase; BMI: Body mass index; ALT: Alanine aminotransferase; DM II: Diabetes mellitus type II; HOMA-IR: Homeostatic Measurement Assessment of Insulin Resistance; IFG: Impaired fasting glucose; GGT: Gamma glutamyl-transferase; INR: International normalized ratio; AAR: AST/ALT ratio.